Little Green Pharma (ASX:LGP) receives manufacturing permit


11 May 2020

Approved stamp image
Little Green Pharma has been granted a new manufacturing permit from the office of drug control

Medicinal cannabis company, Little Green Pharma (LGP) has been granted a new manufacturing permit from the office of drug control.

The manufacturing permit will allow the company to manufacture cannabis extracts for holders of therapeutic goods administration (TGA) GMP manufacturing licences to produce medicinal cannabis products.

Little Green has an exclusive agreement with its GMP-licenced manufacturing partner to produce the products.

The permit is valid for one year and ends in March 2021. This new permit will also allow the company to commence in-house extraction once the next crop is harvested, which is set to reduce costs and improve efficiencies.

Managing Director Fleta Solomon said receiving this permit also gives the company the capability to manufacture cannabis extracts at its manufacturing premises.

"We are now only waiting for our expanded ODC Medicinal Cannabis Cultivation and Production Permit which, once granted, will allow us to begin first planting at our expanded cultivation facility and to significantly expand our production operations," she said.

Read the full article by Lisa Simcock, Markets Reporter here:

You might also be interested in


Company news

Another successful harvest

Little Green Pharma successfully harvest another medical cannabis crop and pass TGO 93.

Jun 2019



TGA announces final CBD down-scheduling
Registered CBD products to be dispensed over-the-counter without a prescription

Dec 2020

Researcher viewing cannabis


Little Green Pharma Stands Out Amid The Crowded Cannabis Canopy

Little Green Pharma (ASX:LGP) has some genuine pioneering notches on its belt. Read the article here

May 2020

View all articles